Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

Lab21 and IntegraGen Collaborate on Colorectal Cancer Diagnostic

By Labmedica International staff writers
Posted on 04 Mar 2013
Lab21 Ltd (Cambridge, UK), a specialist in personalized medicine and clinical diagnostics, has entered into an agreement with biotechnology company IntegraGen (Evry, France), to develop a microRNA assay for colorectal cancer. Financial details were not disclosed.

According to the agreement, Lab21 will develop a CE marked assay, using its proprietary SPARQ polymerase chain reaction (PCR) technology, to detect expression levels of a microRNA biomarker called hsa-mir-31-3p, which was discovered and patented by IntegraGen and its academic partners. This microRNA biomarker might predict response to epidermal growth factor receptor (EGFR) inhibitor therapy in KRAS-wild type patients who have metastatic colorectal cancer.

SPARQ is a fifth generation real time polymerase chain reaction (PCR) technology developed by Cooperative Diagnostics and licensed by Lab21 for use worldwide as announced in January 2012. The technology provides high performance in terms of sensitivity and specificity and allows for rapid assay development.

Most patients with metastatic colorectal cancer are currently screened and stratified by determining mutations in the KRAS gene. Approximately 40% of these patients carry a KRAS mutation and are not candidates for EGFR inhibitor therapy. Of the approximately 60% of patients who do not carry a KRAS mutation (i.e., KRAS wild type) and who are eligible for EGFR inhibitor therapy, effectiveness is still only 50%–60%. MicroRNA expression testing may provide a further level of stratification and thus help clinicians to identify KRAS wild type patients most likely to respond to treatment: improving outcomes, avoiding adverse reactions, and saving money in the healthcare system.

Bernard Courtieu, CEO of IntegraGen commented, ''On the basis of good clinical results and regulatory approval we hope to have a CE Marked kit available based on Lab21’s technology by early 2014. With over 500,000 patients diagnosed with metastatic colorectal cancer annually on a global basis, there is a large market potential for an assay based on this biomarker.''

Lab21 provides diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. Its products division is focused on infectious diseases for blood-banking and clinical markets. The company manufactures immunodiagnostic kits and reagents that are distributed internationally. Its clinical laboratory division has a growing test portfolio providing companion diagnostics and high technology molecular assays.

IntegraGen is a biotechnology company specialized in the research and identification of genetic biomarkers for the development and marketing of products and services for molecular diagnosis. The company's aim is to offer clinicians new personalized tools for diagnosis, treatment, and therapy. The company has a wholly owned US subsidiary located in Cambridge (MA, USA).

Related Links:
Lab21
IntegraGen


VIRCELL
Sekisui Diagnostics
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Clinical Chemistry

view channel
Image: Enzyme-linked immunosorbent kit (ELISA) specific for human copeptin (Photo courtesy of USCN Life Science).

Preeclampsia Biomarker Detected Very Early In Pregnancy

A biomarker has been discovered that could give expecting mothers and their doctors the first simple blood test to reliably predict that a pregnant woman may develop preeclampsia, at least as early as... Read more

Pathology

view channel
Image: Glioblastoma multiforme (GBM) (Photo courtesy of the University of California, San Diego School of Medicine).

Brain Tumor Chemotherapy Biomarkers Identified

Cancer researchers have identified a new biomarker that they believe can predict whether glioblastoma multiformes (GBMs), the most common and aggressive type of malignant brain tumor, will be susceptible... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.